Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...
Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...
1don MSN
Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...
Pfizer ( PFE 3.18%) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback